An interventional study of Treatment with MoodHeadBand (T-PEMF treatment) and Inactive treatment with MoodHeadBand (Placebo) in Moderate Depression, Severe Depressive Episode Without Psychotic Symptoms and Recurrent Depressive Disorder, Current Episode Moderate, sponsored by Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital. Recruiting at 1 site in Denmark. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-08-26.
Sponsored by Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Depressive Disorder with a site in Denmark — 3 open to participants now, 4 under way, none of them phase 3. Depressive Disorder · Denmark.
Among the 27 studies in Depressive Disorder with a site in Denmark, this one is the 8th largest by planned enrollment of the 23 interventional ones that give a count, is one of 3 that started in 2024, is one of 19 with no phase, and was the 22nd registered.
857 studies on the registry are indexed under Depressive Disorder; 160 are open to participants now.
Browse Depressive Disorder studies →3 of the 27 studies in Depressive Disorder with a site in Denmark are open now. Recruiting first, the newest first:
Aalborg University Hospital · Sites in Denmark
Ages 18–65
Ellen Margrethe Hauge · Sites in Denmark
Ages 50–75
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 116 Depressive Disorder studies recruiting now, 44 (38%) set no upper age limit and 66 (57%) stop at 75 or younger; 24 take children under 18; 25 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 1 · Phase 4 1
First in 2002; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 117 is above the median of 87 across 691 interventional studies indexed under Depressive Disorder.
Median enrollment 64 across the 23 interventional studies, 83 across the 4 observational. Of the 22 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 27 has an industry lead sponsor. The 10 most frequent:
Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital is the lead sponsor of 19 studies on the registry; 7 are open to participants now.
Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital has 1 study filed under Depressive Disorder — fewer than ten, so there is no comparison to draw.
2 of the studies in Depressive Disorder with a site in Denmark that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07082777University of AarhusRecovery in Telling Life Stories | 2027-04-01 |
| NCT07263321Aalborg University HospitalImproving Treatment for Depression in General Practice Using a Step-by-Step Care Plan. | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 27 studies in Depressive Disorder with a site in Denmark, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
An 8-week, two-armed, randomized-controlled trial that examines the antidepressant effect of treatment with transcranial pulsed electromagnetic fields (T-PEMF) in patients diagnosed with moderate to severe depression using using a new device, the MoodHeadBand (MHB).
The participants will use an active or placebo MHB for 30 minutes daily for 8 weeks.
Additionally, the following research questions will be answered:
1. If there is a positive effect on the patients' emotional and non-emotional cognition after 8 weeks of active treatment compared to the sham group and if possible early changes in the emotional cognition can predict the treatment response after 8 weeks of treatment.
1. If the T-PEMF treatment provides improvement in restorative sleep after 8 weeks of treatment
The purpose of this study is to clarify whether daily treatment over eight weeks with weak pulsating electromagnetic fields (T-PEMF) can achieve a safe effect on depression compared to the same treatment with a placebo T-PEMF. The study will furthermore explore possible effects on cognition and the hypothesized sleep-ameliorating effect of T-PEMF. Previous Danish studies have shown a significant antidepressant effect of other T-PEMF devices in the treatment of patients with depression.
The study is designed as a blinded, randomized study where active treatment is compared with inactive (placebo) treatment. At the same time, possible side effects in the use of the headband (MoodHeadBand, MHB) are investigated.
The project was initiated June 2024. Patients consecutively referred are asked after an initial interview whether they wish to participate in the study. If they give informed consent to this, they will be randomized to active or placebo treatment. The treatment itself takes place at home, 30 minutes once a day, for 8 weeks. "Treatment as usual" takes place in parallel to the study treatment, and consists of psychotherapy in a group or individually and antidepressive medications. Follow-ups will be conducted weekly either as visits at the clinic, via videocall or as telephone calls. The participants will receive weekly surveys they are encouraged to fill out prior to the weekly follow-ups. The severity of the depression, including its symptomatology will be examined weekly during the study, the cognitive test-battery is applied at baseline, week 1 and at the final visit, the patients sleep-pattern and possible disturbances are examined via the weekly surverys.
No significant side effects have been registered when using the same type of electromagnetic field treatment in the previous Danish studies. It has also been shown that it is possible to carry out the treatment at home without significant problems.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In total, 48 patients will be allocated to this arm. (In total, 117 patients will be included in the study. Data for the initial 21 patients included in the study could not be used to assess the antidepressant effect, why an increased number of participants was needed to secure the power for the trial. The technical difficulties have been addressed)
Device: Treatment with MoodHeadBand (T-PEMF treatment)
In total, 48 patients will be allocated to this arm. (In total, 117 patients will be included in the study. Data for the initial 21 patients included in the study could not be used to assess the antidepressant effect, why an increased number of participants was needed to secure the power for the trial. The technical difficulties have been addressed)
Device: Inactive treatment with MoodHeadBand (Placebo)
The patients will receive treatment with T-PEMF using a headband containing 20 coils placed symmetrically around the head of the patient. The device delivers 55 Hz magnetic field. Duration of treatment is 30 minutes once a day for 8 weeks.
Patients will use an identical device, which does not deliver T-PEMF treatment. The patients will use the headband as the active group for 30 minutes, once a day, for 8 weeks.
Inventory of Depressive Symptomatology (Self-Report) (IDS-SR)
The IDS-SR is a 30-item self-report scale for measuring depressive symptoms, with satisfying psychometric features and good correlations with Hamilton-D17 (HAM-D17).
Time frame: 8 weeks
Hamilton-D17 (HAM-D17)
A scale measuring depressive symptoms. Will be applied at baseline and at the end point
Time frame: 8 weeks
Hamilton-D6 (HAM-D6)
A scale measuring depressive symptoms. Will be applied at baseline and at the end point.
Time frame: 8 weeks
Quick Inventory of Depressive Symptomatology
A quick-version of the IDS questionnaire, that consists of 16 questions. Patients fill this assesment on a weekly basis during the study.
Time frame: 8 weeks
WHO-5
This Well-Being Index consists of five items that are scored on a frequency response scale from "none of the time" (0) to "all of the time" (5).
Time frame: 8 weeks
Facial Expression and Recognition Test (FERT)
A test that assesses the patients recognition of - and attention to facial expressions as a part of the cognitive test battery that explores the patients "hot" cognition.
Time frame: 8 weeks
Emotional Categorization and Memory Test (ECMT)
A test that assesses the patient' self-referential memory with emotion laded words as a part of the cognitive test battery that explores the patients' "hot" cognition.
Time frame: 8 weeks
Screening of cognitive impairment in Psychiatry (SCIP)
A screening tool used to assess cognitive performance in psychiatric patients. The test includes List learning, delayed list learning, verbal fluency, visuomotor tracking tests. Explores the patients' "cold" cognitive mechanisms.
Time frame: 8 weeks
Trail Making Test B (TMT-B)
A test that assesses the patients' visual attention and ability to switch tasks. Explores the patients' "cold" cognitive mechanisms.
Time frame: 8 weeks
Sleep diary
The diary explores the patients sleep pattern and quality of sleep.
Time frame: 8 weeks
Udvalget for Kliniske Undersøgelser scale (UKU-24)
Side effects are assessed by the UKU-24 scale, including free text comments. Side effects will be assesed at week 1, 2, 4, 6 and at the end point.
Time frame: 8 weeks
Plan to share: No — It is not possible to share individual participant data due to GDPR. Anonymised data after publishing might be available per request.
Started Jun 2024 (actual). Primary completion is estimated for Aug 2026, 26 months after the start.
Of 261 non-industry interventional studies with no phase under Depressive Disorder, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 45. This study's planned 26 months is below that.
Counting every sponsor, half of 276 studies reached it within 29 months; a quarter within 15 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital